Curis Lifesciences IPO
IPO Listing Details
- Listing Date
14 Nov 2025
- Listing Price
₹ 146.10
- Listing Change
14.14%
- Last Traded Price
₹ 115.00
Curis Lifesciences IPO Details
-
Open Date
07 Nov 2025
-
Close Date
11 Nov 2025
-
Listing Date
14 Nov 2025
- IPO Price Range
₹ 120 to ₹128
- IPO Size
₹ 27.52 Cr
- Listing Exchange
NSE SME
Curis Lifesciences IPO Timeline
Curis Lifesciences IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 07-Nov-2025 | 8.34 | 1.19 | 0.85 | 3.06 |
| 10-Nov-2025 | 8.34 | 4.06 | 3.75 | 5.13 |
| 11-Nov-2025 | 96.17 | 115.46 | 44.28 | 74.39 |
Last Updated: 11 November 2025 6:06 PM by 5paisa
Curis Lifesciences Limited, launching a ₹27.52 Cr IPO, is a pharmaceutical company engaged in developing, manufacturing, and distributing a wide range of products. Operating from its state-of-the-art facility in Sanand, Gujarat, the company ensures strict quality and safety standards. It produces tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments. Curis serves over 100 corporate clients globally through loan licences and contract manufacturing, with branded operations in Yemen and Kenya.
Established in: 2010
Managing Director: Mr. Dharmesh Dasharathbhai Patel
Peers:
Sotac Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited
Curis Lifesciences Objectives
1. The company will upgrade existing manufacturing facilities (₹2.44 crores).
2. It plans to construct a new storage facility (₹3.62 crores).
3. Funds will be used to repay secured loans (₹1.86 crores).
4. The company aims to register products internationally (₹2.69 crores).
5. It will fund working capital requirements (₹11.25 crores).
6. Remaining funds will support general corporate purposes.
Curis Lifesciences IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹27.52 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹27.52 Cr |
Curis Lifesciences IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
| Retail (Min) | 2 | 2,000 | 2,40,000 |
| Retail (Max) | 2 | 2,000 | 2,56,000 |
| S-HNI (Min) | 3 | 3,000 | 3,60,000 |
| S-HNI (Max) | 7 | 7,000 | 8,96,000 |
| B-HNI (Min) | 8 | 8,000 | 9,60,000 |
Curis Lifesciences IPO Reservation
| Investors Category | Subscription (times) | Shares Offered* | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB (Ex Anchor) | 96.17 | 4,09,000 | 3,93,35,000 | 503.49 |
| Non-Institutional Buyers | 115.46 | 3,08,000 | 3,55,63,000 | 455.21 |
| bNII (bids above ₹10L) | 142.74 | 2,06,000 | 2,94,04,000 | 376.37 |
| sNII (bids below ₹10L) | 60.38 | 1,02,000 | 61,59,000 | 78.84 |
| Retail Investors | 44.28 | 7,16,000 | 3,17,06,000 | 405.84 |
| Total** | 74.39 | 14,33,000 | 10,66,04,000 | 1,364.53 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
Curis Lifesciences IPO Anchor Allocation
| Particulars | Details |
| Anchor Bid Date | 6 November 2025 |
| Shares Offered | 6,10,000 |
| Anchor Portion Size (In ₹ Cr.) | 7.81 |
| Anchor Lock-in Period End Date for 50% Shares (30 Days) | 12 December 2025 |
| Anchor Lock-in Period End Date for Remaining Shares (90 Days) | 10 February 2026 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Revenue | 35.45 | 35.56 | 49.13 |
| EBITDA | 3.27 | 8.39 | 9.54 |
| Profit After Tax (PAT) | 1.88 | 4.87 | 6.11 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Total Assets | 29.75 | 33.88 | 42.53 |
| Share Capital | 0.50 | 0.50 | 5.93 |
| Total Liabilities | 12.14 | 9.81 | 9.46 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | 3.35 | 0.28 | -1.76 |
| Net Cash Generated From / (used in) Investing Activities | -0.56 | -0.06 | -0.02 |
| Net Cash Generated From / (used in) Financing Activities | -2.76 | 0.05 | 1.67 |
| Net Increase / (Decrease) In Cash And Cash Equivalents | 0.04 | 0.27 | -0.11 |
Strengths
1. State-of-the-art manufacturing facility in Gujarat.
2. Diverse product portfolio across multiple formulations.
3. Strong client network in domestic and global markets.
4. Strict adherence to quality and safety standards.
Weaknesses
1. Limited brand presence in highly competitive markets.
2. Dependence on loan licence and contract manufacturing.
3. Regulatory approvals can delay international market entry.
4. High capital investment required for facility upgrades.
Opportunities
1. Expanding presence in emerging global pharmaceutical markets.
2. Increasing demand for affordable, quality healthcare products.
3. Product registration in new countries boosts reach.
4. Technological upgrades can enhance production efficiency.
Threats
1. Intense competition from domestic and global pharma firms.
2. Frequent changes in international regulatory requirements.
3. Currency fluctuations affecting export profitability.
4. Rising raw material costs impacting profit margins.
1. Strong presence in global pharmaceutical manufacturing markets.
2. Advanced facility ensuring quality and regulatory compliance.
3. Expansion plans to increase production and efficiency.
4. Rising demand for affordable healthcare products worldwide.
Curis Lifesciences Limited operates in the growing pharmaceutical sector, focusing on manufacturing high-quality formulations for global and domestic markets. With a modern facility in Gujarat and over 100 corporate clients, the company maintains strong technical expertise and regulatory compliance. The IPO aims to fund capacity.
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Curis Lifesciences IPO opens from November 7, 2025 to November 11, 2025.
The size of Curis Lifesciences IPO is ₹27.52 Cr.
The price band of Curis Lifesciences IPO is fixed at ₹120 to ₹128 per share.
To apply for Curis Lifesciences IPO, follow the steps given below:
● Login to your 5paisa demat account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Curis Lifesciences IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Curis Lifesciences IPO is of 2,000 shares and the investment required is ₹2,40,000.
The share allotment date of Curis Lifesciences IPO is November 12, 2025
The Curis Lifesciences IPO will likely be listed on November 14, 2025.
Finaax Capital Advisors Private Limited is the book running lead managers for Curis Lifesciences IPO.
Curis Lifesciences IPO plans to utilise the raised capital from the IPO for:
- The company will upgrade existing manufacturing facilities (₹2.44 crores).
- It plans to construct a new storage facility (₹3.62 crores).
- Funds will be used to repay secured loans (₹1.86 crores).
- The company aims to register products internationally (₹2.69 crores).
- It will fund working capital requirements (₹11.25 crores).
- Remaining funds will support general corporate purposes.
Curis Lifesciences Contact Details
Curis Lifesciences Ltd.
PF-23, GIDC Sanand - II,
Industrial Estate,
Sanand
Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Curis Lifesciences IPO Register
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: curislifesciences.smeipo@in.mpms.mufg.com
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Curis Lifesciences IPO Lead Manager
Finaax Capital Advisors Private Limited